Creating new treatments for muscle loss in cancer patients
Development of novel therapeutics for cancer cachexia
This study is looking at a new medication to help cancer patients who are losing muscle strength and feeling weak, with the hope of improving their overall health and quality of life.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emmyon, INC. NIH-funded |
| Lab location | 1 site (Rochester, UNITED STATES) |
| Project ID | NIH-10804742 on NIH RePORTER |
What this research studies
This research focuses on developing new medications to combat cancer cachexia, a condition that causes severe muscle loss in cancer patients. It aims to address the significant unmet need for effective therapies to improve physical function and quality of life for those affected. The researchers have identified a natural compound that reduces muscle atrophy in animal models and are now working on a more potent derivative to enhance its effectiveness. By testing this new drug, they hope to provide a viable treatment option for patients suffering from this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who are experiencing significant muscle loss due to cancer cachexia.
Not a fit: Patients with early-stage cancer or those not experiencing muscle atrophy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that improve muscle mass and overall quality of life for cancer patients experiencing cachexia.
How similar studies have performed: Previous research has shown promise in using natural compounds to address muscle atrophy, but this specific approach with the new derivative is novel.
Where this research is happening
Rochester, UNITED STATES
- Emmyon, INC. — Rochester, United States (Active)
Researchers
- Principal investigator: Ebert, Scott Matthew — Emmyon, INC.
- Study coordinator: Ebert, Scott Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.